Physician profile
Ayub Merchant
NPI 1871575175
$7,042.67
in general payments reported to CMS, 2019-2025
35 companies · $1,743 in 2025
The $1,743 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,377 · 2020: $216 · 2021: $157 · 2022: $857 · 2023: $1,261 · 2024: $1,432 · 2025: $1,743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,421 · Education: $14.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,420.95 |
| Education | $14.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,432.68 | 2019-2025 | |
| Janssen Biotech, INC. | $737.29 | 2019-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $662.33 | 2019-2024 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $401.58 | 2019-2025 | Entyvio, Eohilia |
| Qol Medical, LLC | $348.97 | 2019-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $291.33 | 2022-2025 | Dupixent |
| Pfizer INC. | $261.62 | 2019-2025 | |
| Ardelyx, INC. | $190.07 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $160.96 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $143.29 | 2021-2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $127.48 | 2024-2025 | Voquezna |
| Alnylam Pharmaceuticals INC. | $122.24 | 2022-2024 | Givlaari |
| Endogastric Solutions, INC | $114.06 | 2019 | |
| Gilead Sciences, INC. | $101.70 | 2022-2025 | |
| Lilly USA, LLC | $99.51 | 2024-2025 | Omvoh |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $98.62 | 2023-2025 | Rebyota |
| Lucid Diagnostics INC. | $76.55 | 2024 | |
| Daiichi Sankyo INC. | $71.97 | 2022-2023 | Injectafer |
| Ipsen Biopharmaceuticals, INC | $64.22 | 2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $59.27 | 2023-2024 | Linzess |
| Celgene Corporation | $55.00 | 2019 | |
| Celltrion USA INC. | $45.81 | 2024-2025 | Vegzelma, Zymfentra |
| Intercept Pharmaceuticals, INC. | $45.42 | 2019-2020 | |
| Medtronic, INC. | $44.79 | 2024-2025 | Gi Genius |
| Nestle Healthcare Nutrition INC. | $44.29 | 2021-2022 | |
| Madrigal Pharmaceuticals | $41.21 | 2024-2025 | Resmetirom, Rezdiffra |
| Amgen INC. | $41.15 | 2022-2023 | Amjevita, Avsola |
| Redhill Biopharma INC. | $31.90 | 2021 | |
| Aimmune Therapeutics, INC. | $31.41 | 2025 | Zenpep |
| Shire North American Group INC | $17.81 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.39 | 2024 | Cyltezo |
| Romark Laboratories, Lc | $16.62 | 2019 | |
| Mylan Institutional INC. | $15.67 | 2023 | Hulio |
| Ucb, INC. | $15.33 | 2019 | |
| W. L. Gore & Associates, INC. | $13.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayub Merchant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.